12:00 AM
 | 
Apr 24, 2000
 |  BC Week In Review  |  Company News  |  Deals

North American Vaccine, Baxter, BioChem deal

The companies reduced by $0.27 to $6.73 the per-share consideration NVX shareholders will receive from BAX under BAX's proposed acquisition of NVX (see BioCentury, Nov. 22, 1999). NVX shareholders now will receive $6.70 in BAX stock and $0.03 per share. The companies also extended by...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >